ArticleDiscover oncology2026
Synergistic efficacy of radiotherapy and immunotherapy enhances clinical outcomes in patients with advanced non-small cell lung cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundImmunotherapy has become a primary treatment for advanced non-small cell lung cancer (NSCLC), although drug resistance is inevitable. Radiotherapy enhances immunotherapy efficacy, particularly in early to mid-stage NSCLC. However, the synergistic effects of radiotherapy and immunotherapy in advanced NSCLC remain controversial.
methodsWe retrospectively analyzed data from 141 stage IV NSCLC patients treated with first-line immunotherapy or chemoimmunotherapy at Hangzhou Cancer Hospital. Patients were divided into groups receiving radiotherapy combined with immunotherapy versus immunotherapy alone. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Cox regression method. Subgroup Cox regression analyses were performed to optimize the combination regimens.
resultsThe combined therapy group showed longer PFS (16.9 vs. 8.49 months, HR 0.57, p = 0.006) and OS (69.93 vs. 24.62 months, HR 0.60, p = 0.04). Subgroup analysis indicated that non-squamous NSCLC patients without immunotherapy rechallenge benefited most. Radiotherapy added to immunotherapy in lung or brain metastases showed a trend toward improved PFS (lung: 19.34 vs. 6.03 months, HR 0.62, p = 0.30; brain: 22.72 vs. 7.80 months, HR 0.59, p = 0.29). Concurrent (HR 0.41, p = 0.02) or consolidation radiotherapy (HR 0.32, p = 0.003) during immunotherapy offered greater PFS benefits than symptom-relief radiotherapy. Both stereotactic body radiotherapy and conventional radiotherapy yielded similar survival outcomes. Incidence of grade 3 or higher pneumonia post-lung-radiotherapy was 3.45%.
conclusionsOur study highlights the synergistic efficacy of combining radiotherapy with immunotherapy in advanced NSCLC. Optimizing patient selection, targeting specific sites, effective timing, and tailored radiotherapy regimens significantly improved PFS and OS, providing crucial insights for enhancing clinical outcomes in advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.